Zestagen is a Swiss biotechnology company developing light chain mAbs against Extracellular Heat Shock Protein-90 (ehsp90). hsp90 is a validated pharmaceutical target. ehsp90 is implicated in cancer cell motility, migration and metastasis. It is detectable at the surface of several cancer cells but not of normal adult cells. Zestagen's mAbs bind ehsp90 at the surface of cancer cells (but not normal cells) leading to significant inhibition of metastasis in preclinical cancer animal models. Unlike small molecule hsp90 inhibitors which do not discriminate between the extracellular and intracellular hsp90 pool, Zestagen’s mAbs are predicted to display a superior therapeutic index in cancer patients.
ZESTAGEN AT A SNAPSHOT
Download this pdf for a company summary and contact information.